Speciality: Cardiology
Description:
.A warm welcome to all the medical professionals in this interesting live Session on Transthyretin Amyloid Cardiomyopathy (ATTR-CM) by Pfizer.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a progressive and often underdiagnosed condition characterized by the deposition of abnormal transthyretin protein in the heart tissue. Pfizer, a leading pharmaceutical company, is at the forefront of research and development in the field of ATTR-CM.
Through innovative therapies and groundbreaking clinical trials, Pfizer aims to improve the diagnosis, management, and outcomes for patients affected by this debilitating disease. With a commitment to advancing medical science and enhancing patient care, Pfizer's efforts in the field of ATTR-CM offer hope for those living with this challenging condition.
Therefore, get an overall knowledge on detecting fetal aneuploidies in maternal blood. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions
See More Webinars @ Hidoc Webinars
1.
Retired Olympic athletes at greater risk of skin cancer and osteoarthritis, research reveals
2.
Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye Cancer
3.
Celebrity Cancers Stoking Fear? Cisplatin Shortage Ends; Setback for Anti-TIGIT
4.
Year in Review: Non-Small Cell Lung Cancer
5.
Electronic Sepsis Alerts; Reducing Plaques in Coronary Arteries
1.
What Is Carboxyhemoglobin And How Can It Affect Your Health?
2.
Introducing the Corrected Calcium Calculator: A Revolutionary Tool in Medical Assessment
3.
Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment
4.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
5.
The Importance of Having a Quick and Effective Heparin Antidote
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
2.
Navigating the Complexities of Ph Negative ALL - Part XVI
3.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation